Evidence map›Paper›PMID 33459871›Full record

ArticleThe AAPS journal2021

Competition-Based Cell Assay Employing Soluble T Cell Receptors to Assess MHC Class II Antigen Processing and Presentation.

Carley Tasker, Jenny Patel, Vibha Jawa, Jad Maamary

Open access · bronzeAbstract read
In one paragraph

Article in The AAPS journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Carley TaskerPredictive and Clinical Immunogenicity, Merck & Co., Inc., Kenilworth, New Jersey, USA.
Jenny PatelPredictive and Clinical Immunogenicity, Merck & Co., Inc., Kenilworth, New Jersey, USA.
Vibha JawaPredictive and Clinical Immunogenicity, Merck & Co., Inc., Kenilworth, New Jersey, USA.
Jad MaamaryPredictive and Clinical Immunogenicity, Merck & Co., Inc., Kenilworth, New Jersey, USA. jad.maamary@merck.com.
Merck & Co., Inc., Rahway, NJ, USA (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate assessment of antigen-specific immune responses is critical in the development of safe and efficacious biotherapeutics and vaccines. Endosomal processing of a protein antigen followed by presentation on major histocompatibility complex (MHC) class II constitute necessary steps in the induction of CD4+ T cell immune responses. Current preclinical methods for assessing immunogenicity risk consist of in vitro cell-based assays and computational prediction tools. Cell-based assays are time and labor-intensive while in silico methodologies have limitations. Here, we propose a novel cell-based assay capable of investigating an antigen's endosomal processing and MHC class II presentation capabilities. This novel assay relies on competition between epitopes for MHC class II binding and employs labeled soluble T cell receptors (sTCRs) as detectors of epitope presentation.

Indexed as

Antigen PresentationAnimalsBiological AssayCD4-Positive T-LymphocytesCHO CellsComputer SimulationCricetulusDendritic CellsEndosomesEpitope MappingEpitopes, T-LymphocyteEpoetin AlfaHealthy VolunteersHistocompatibility Antigens Class IIHumansImmunoassayEpitopes, T-LymphocyteEpoetin AlfaHistocompatibility Antigens Class IIReceptors, Antigen, T-Cellantigen presentationAPCHLA-DRMHCTCR

Identifiers

PMID33459871
PMCPMC7812987
OpenAlexW3124513610

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.